- Record: found
- Abstract: found
- Article: not found
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Sergio Amadori
1 ,
Stefan Suciu ,
Roberto Stasi ,
Helmut R Salih ,
Dominik Selleslag ,
Petra Muus ,
Paolo De Fabritiis ,
Adriano Venditti ,
Anthony D Ho ,
Michael Lübbert ,
Xavier Thomas ,
Roberto Latagliata ,
Constantijn J M Halkes ,
Franca Falzetti ,
Domenico Magro ,
José E Guimaraes ,
Zwi Berneman ,
Giorgina Specchia ,
Matthias Karrasch ,
Paola Fazi ,
Marco Vignetti ,
Roel Willemze ,
Theo de Witte ,
Jean-Pierre Marie
Dec 10 2013
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML).